Small CDMO
Market Cap
₹29,243 ₹29,243 Cr.
P/E
0.00
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis turns live if CDMO order inflows recover sustainably and the large customer's destocking does not recur, alongside timely ex-US Sevoflurane approvals.- The bull path requires faster CDMO commercial conversion and ROW approvals, with utilization and mix driving operating leverage.
- The bear path is driven by renewed destocking or weak biotech funding, delayed approvals, and persistent pricing or consumer-healthcare pressure.

Get your Reports on Demand
Get detailed, analyst-grade reports with actionable insights to make informed investment decisions.
  Flat 20% OFF
 for Tijori Premium Users
My Reports
  Flat 20% OFF  for Tijori Premium Users
5Y Revenue & EBITDA Estimates
KEY TRIGGERS TO WATCH
  • The thesis turns live if CDMO order inflows recover sustainably and the large customer's destocking does not recur, alongside timely ex-US Sevoflurane approvals.
  • The bull path requires faster CDMO commercial conversion and ROW approvals, with utilization and mix driving operating leverage.
  • The bear path is driven by renewed destocking or weak biotech funding, delayed approvals, and persistent pricing or consumer-healthcare pressure.
Bear : 5.0% CAGR ₹1,450 Cr
Base: 22.7% CAGR ₹3,151 Cr
Bull: 30.5% CAGR ₹4,300 Cr
Management Credibility Report
TRACK RECORD
  • Management is most credible on controllable execution: capacity commissioning and consumer-healthcare operating initiatives have generally landed as promised.
  • Trust is weaker on CDMO growth, margins, leverage and long-range targets, which are exposed to customer destocking and biotech funding cycles.
  • The split reflects a pattern of reliable operational delivery but overly confident, insufficiently revised market-dependent guidance when conditions deteriorate.
Met : 8
Progress: 4
Missed : 7
Risk Probe Report
WORST-CASE SCENARIO
  • The risk profile is unusually fragile for a mature, diversified pharma platform: earnings quality, working capital, liquidity and leverage are deteriorating together rather than in isolation.
  • Solvency is the existential fault line; sub-1x interest coverage and elevated debt leave little room if CDMO demand fails to recover.
  • The compound funding-stall, Sevoflurane price-war and inventory write-down scenario is most severe, while recovery depends on CDMO orders, inventory normalization and restored cash generation.
High Risk : 5
Medium Risk : 7
Low Risk : 5
Powered By
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material